Skip to content

Tiaobuxinshen Formula for the treatment of Alzheimer's disease clinical study.

Tiaobuxinshen Formula for the treatment of Alzheimer's disease clinical study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002572
Enrollment
Unknown
Registered
2025-12-27
Start date
2023-07-01
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease (AD)

Interventions

Treatment group:Donepezil hydrochloride tablets combined with Qiaobuxinshen decoction orally, twice daily.
Control Group:Donepezil Hydrochloride Tablets orally, 5 mg every evening before bedtime, then increased to 10 mg after 4 weeks.

Sponsors

Jilin Province Academy of Traditional Chinese Medicine First Clinical Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Meets the core clinical criteria for probable AD dementia according to NIA-AA (2011). 2. Age between 65 and 85 years (inclusive of 65 and 85), with no restriction on gender. 3. Clinical Dementia Rating Scale - Global Score (CDR-GS) total score of 2 points. 4. Mini-Mental State Examination (MMSE) score between 11 and 20 points. 5. PES-D-11 subscale score for kidney deficiency and marrow depletion =7. 6. Skull MRI coronal MTA-scale score =1.5 points (age-adjusted values: =1.5 points for 65-74 years, =2.0 points for 75-84 years). 7. The patient has sufficient vision and hearing to participate in clinical assessments, has normal swallowing function, and is able to complete medication intake.

Exclusion criteria

Exclusion criteria: 1. Early-onset (onset before 65 years of age) and mild to severe AD dementia; 2. Non-AD dementia; 3. Presence of unstable mental disorders; 4. History of heavy alcohol consumption or substance abuse within the past 5 years; 5. Other uncontrolled systemic diseases; 6. Severe abnormalities in liver or kidney function; 7. Regular use of cognitive-enhancing drugs within the past month; 8. Use of concomitant medications prohibited in this clinical study; 9. Unable to complete MRI examinations; 10. Intolerance or allergy to the study drug; 11. Currently participating in other studies; 12. Participants deemed unsuitable for inclusion by the investigator.

Design outcomes

Primary

MeasureTime frame
Clinical Dementia Rating Scale (CDR Scale);Mini-Mental State Examination;

Secondary

MeasureTime frame
Activities of Daily Living Scale;Dementia Symptom Elements Scale;

Countries

China

Contacts

Public ContactXiang Ke

Jilin Province Academy of Traditional Chinese Medicine First Clinical Hospital

xiangke1961@163.com17386896630

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026